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A randomized, parallel, double-blind study was performed 
with lisinopril, a long-acting angiotensin-converting en- 
zyme inhibitor, versus captopril, a shorter-acting angioten- 
sin-converting enzyme inhibitor, in the treatment of con- 
gestive heart failure. All patients were in New York Heart 
Association class II, III or IV and had remained sympto- 
matic despite therapy with digoxin and diuretics. After a 4 
to 14 day placebo baseline period, patients were random- 
ized to receive either lisinopril, 5 mg orally once per day (n 
= 94), or captopril, 12.5 mg orally three times per day (n = 
95), in addition to continuation of digoxin and diuretics. 
The dose of study drug could be doubled at 4 week intervals 
for a total of 12 weeks of double-blind therapy. The 
maximal dose was 20 mg once per day of lisinopril or 50 mg 
three times per day of captopril. 
The addition of either lisinopril or captopril to a regi- 
men of diuretics or digoxin, or both, caused an increase in 
exercise duration as assessed on a motorized treadmill. 
When protocol violators were excluded, patients receiving 
lisinopril had a statistically greater increase in exercise 
duration than that of patients receiving captopril. In pa- 
tients with renal impairment (serum creatinine >1.6 mg/dl 
at baseline), lisinopril was superior to captopril in improv- 
ing exercise duration. Lisinopril, but not captopril, in- 
creased left ventricular ejection fraction in patients with 
moderately to severely (~35%) decreased function (p < 
0.05). Improvement in functional capacity and quality of 
life, as assessed by the Yale Scale dyspnedfatigue index, 
was significantly greater for the lisinopril group. 
Lisinopril and captopril were comparable with respect 
to the safety profiles. Elevations in blood urea nitrogen, but 
not creatinine, were more frequent with lisinoprii. How- 
ever, these elevations in blood urea nitrogen were reversible 
with adjustment of diuretic dosage and were not associated 
with significant morbidity or discontinuation of angioten- 
sin-converting enzyme inhibitor therapy. 
(J Am Co11 Cardiol1989;13:1240-7) 
Both long- and short-acting angiotensin-converting enzyme 
inhibitors are effective therapy for patients with congestive 
heart failure (14). However, questions remain concerning 
the role of long-acting angiotensin-converting enzyme inhib- 
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itors (>12 h suppression of converting enzyme activity, for 
example, enalapril) as compared with shorter-acting an- 
giotensin-converting enzyme inhibitors (~8 h suppression of 
converting enzyme, for example, captopril) in the treatment 
of congestive heart failure (4). Long-acting angiotensin- 
converting enzyme inhibitors offer the advantage of less 
frequent dosing and perhaps increased therapeutic efficacy 
due to a more even and prolonged suppression of the adverse 
cardiovascular effects that accompany activation of the 
renin-angiotensin system in congestive heart failure. Re- 
cently, a long-acting angiotensin-converting enzyme inhibi- 
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tor, enalapril, was reported (5) to favorably influence sur- 
vival in patients with congestive heart failure. 
On the other hand, long-acting angiotensin-converting 
enzyme inhibitors have been reported (4) to have a more 
adverse effect on renal function than that of short-acting 
angiotensin-converting enzyme inhibitors. These adverse 
effects are attributed to the influence of converting enzyme 
inhibition on systemic and renal hemodynamics and are 
therefore an index of the degree to which the angiotensin- 
converting enzyme inhibitors are capable of inhibiting the 
renin-angiotensin system. Importantly, the changes in renal 
function with angiotensin-converting enzyme inhibitors are 
reversible with discontinuance of these drugs and adjust- 
ment of diuretic doses and rarely contribute to morbidity (6). 
The following study was designed to evaluate lisinopril”. 
a long-acting angiotensin-converting enzyme inhibitor with 
>72 h suppression of converting enzyme activity after a 
single oral dose of 10 mg (7), with the shorter acting 
angiotensin-converting enzyme inhibitor, captopril. in the 
treatment of outpatients with congestive heart failure who 
were in New York Heart Association functional class II, III 
or IV. An interim report of this study (8,9) included 64 
patients taking lisinopril and 65 taking captopril and sug- 
gested that lisinopril would be as effective as captopril in 
treating patients with congestive heart failure. The larger 
group size in the current report (94 patients taking lisinopril 
and 95 taking captopril) makes possible a further analysis of 
efficacy and safety in demographic subgroups, for example, 
those with renal impairment as well as those with severe left 
ventricular dysfunction. 
Methods 
This study was conducted in compliance with ethical 
committee review, informed consent and other statutes and 
regulations regarding the protection of the rights and welfare 
of human subjects participating in biomedical research. 
Study design and patient definition. This was a 12 week, 
double-blind, randomized. controlled, parallel, multiclinic 
study of 189 patients with congestive heart failure in func- 
tional class II, III or IV while receiving diuretics and 
digoxin. The clinical diagnosis of congestive heart failure 
was confirmed by at least one of the following: a radionu- 
elide left ventricular ejection fraction <45%, a cardiotho- 
racic ratio >0.5, the presence of a third heart sound, an 
elevated pulmonary capillary wedge pressure (> 15 mm Hg) 
or reduced cardiac index (~2.5 literslmin per m2) within the 
past year. 
At the beginning of a 4 to 14 day placebo baseline period, 
all antihypertensive and vasodilator medications were with- 
drawn including angiotensin-converting enzyme inhibitors, 
*Prinivil (Merck! or Zestril (ICI). 
calcium channel blockers, hydralazine, prazosin and chronic 
nitrate therapy. Doses of digoxin and diuretics were contin- 
ued at a constant dose, and body weight was to be stable 
within 1 kg during the last 4 days of the baseline period. 
During the baseline period, patients received placebo match- 
ing 5 mg lisinopril taken once per day: and placebo matching 
12.5 mg captopril taken three times per day. 
Exclusion criteria included a history of captopril intoler- 
ance, recent unstable angina, myocardial infarction or cere- 
brovascular accident, clinically important renal, hepatic or 
hematologic disorders, hyperkalemia or hypokalemia, pre- 
dominant car pulmonale and hemodynamically significant 
aortic stenosis. Also excluded were patients with systolic 
arterial pressure ~80 mm Hg, those with evidence of digi- 
talis toxicity, patients receiving other investigational therapy 
or patients who were abusers of alcohol or recreational 
drugs. 
fnclusion criteria included ability to exercise on a motor- 
ized treadmill between 1 and 12 min after a modified Patter- 
son protocol (IO) with exercise duration limited by dyspnea 
or fatigue, or both. At least two baseline treadmill exercise 
tests were required before randomization, and the last two 
tests could not differ by more than 2 min in exercise 
duration. 
Drug administration and monitoring. Patients were ran- 
domized and received either an initial dose of 5 mg lisinopril 
orally and placebo matching 12.5 mg captopril orally; or 12.5 
mg captopril orally and placebo matching 5 mg lisinopril 
orally. All lisinopril (and lisinopril placebo) doses were taken 
1 h before breakfast and captopril (and captopril placebo) 
doses were taken 1 h before breakfast, lunch and dinner. 
Administration of digoxin and diuretics was continued unin- 
terrupted. Study therapy was administered according to this 
schedule even on exercise testing days. 
Hourly systemic arterial pressure wus monitored for 8 h 
cftcr the,first dose of study drug. The dose of study drug was 
increased at 4 week intervals if the patient had not developed 
symptomatic hypotension (standing systolic blood pressure 
~80 mm Hg) and there was evidence of a need, in the 
opinion of the investigator, for additional therapeutic effect. 
Titration steps were lisinopril. 5. 10 and 20 mg orally once a 
day, or captopril, 12.5, 25 or 50 mg three times a day. Each 
patient also received placebo matching the alternate therapy 
in the regimen. Diuretic doses were adjusted as needed for 
the control of edema and body weight. 
Fille treadmill exercise tests btaere performed, two during 
the baseline period and three (at 4 week intervals) during the 
double-blind period. A complete laboratory screening and an 
evaluation of functional status were done at the end of the 
baseline period and at 4 week intervals during the double- 
blind period. Clinical evaluations were performed at 4 week 
intervals during the double-blind period and 2 weeks after 
each dose adjustment. Gated blood pool radionuclide scans 
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and chest roentgenograms were performed at the end of 
baseline and the end of the 12 week, double-blind period. 
Patients who received lisinopril during the double-blind 
period and had a beneficial therapeutic response could be 
continued on open label lisinopril for 2 years at the optimal 
dose established during the double-blind period. Fifty-five 
patients randomized to lisinopril continued into the long- 
term study extension. In addition, seven patients originally 
randomized to captopril received lisinopril during the study 
extension. 
Evaluation criteria. Patients were evaluated with use of 
14 efficacy criteria. The primary variable evaluated was the 
duration of treadmill exercise assessed as the change from 
baseline to the end of weeks 4, 8 and 12 of the double-blind 
treatment period. Also, 13 other efficacy variables were 
assessed as the change from baseline to the end of week 12 
as follows: 
Functional assessment and quality of life. a) New York 
Heart Association functional class (determined by the inves- 
tigator throughout the study). b) Patient’s global evaluation 
of response (patient assessment): Patients were asked “Are 
you much better, moderately better, slightly better, un- 
changed or worse?,” compared with baseline (asked only at 
weeks 4,8 and 12). c) Yale Scale dyspnealfatigue index. This 
is a group of three scales that rate a patient’s ability to 
perform tasks of daily living and therefore evaluate quality of 
life. Three separate scales were used to evaluate functional 
impairment, magnitude of the tasks performed and pace of 
the tasks performed daily with scores combined into a total 
score measuring the severity of impairment due to conges- 
tive heart failure. Higher total scores indicate less impair- 
ment. 
Radiologic tests. (a) Cardiothoracic ratio as measured on 
posteroanterior chest roentgenogram. b) Left ventricular 
ejection fraction by gated radionuclide scan. 
Congestive heart failure symptoms: orthopnea, paroxys- 
mal nocturnal dyspnea. 
Congestive heart failure signs: rales, edema, third heart 
sound, jugular venous distension, weight and heart rate. 
Statistical methods. The data were analyzed using an “all 
patients treated” approach; that is, no patients were ex- 
cluded as protocol violators. In the “all patients treated” 
approach, if a patient’s data were missing for any week 
beyond 4 weeks, the previous weeks’ data were carried 
forward and used for analyses. An analysis also was done 
excluding protocol violators. Patients were excluded for the 
following reasons: inconsistency of baseline exercise tests 
(difference >120 s) (17 patients), use of prohibited concom- 
itant therapy (6 patients) and increase in digoxin dose (3 
patients). 
For continuous variables, baseline comparability and 
between-group differences were assessed with use of a rank 
analysis of variance similar to that proposed by Conover and 
Iman (11). For analyses of between-group differences, the 
dependent variable was the change from baseline, and the 
analysis of variance model included factors for investigator 
and treatment group and a covariate of the last pretreatment 
value. Treatment by investigator interaction was assessed in 
separate analyses using the same model but with an interac- 
tion term added. Within-group changes from baseline were 
analyzed with use of the signed-rank test with data pooled 
with respect to investigator. 
Nonparametric correlations between continuous second- 
ary variables and exercise duration were based on Spear- 
man’s method (12). 
For dichotomous and ordinal variables, baseline compa- 
rability for these variables was assessed using logit-linear 
models (13) with no explanatory variables other than treat- 
ment group in the model. The posttreatment scores of the 
treatment groups were compared with use of the same 
models but with pretreatment included as a covariate. To use 
the ordinal pretreatment value as a covariate, equally spaced 
scores were assigned. For the patient’s assessment of re- 
sponse there was no baseline value; therefore, no baseline 
comparability was assessed and no pretreatment value was 
used as a covariate. 
The difference between treatment groups was expressed 
as an odds ratio. This is the ratio of the probability that a 
patient will have a better response with lisinopril than with 
captopril to the probability that the opposite will be true. 
Hence, an odds ratio >l favors lisinopril. 
Within-group changes from baseline were assessed with 
use of McNemar’s test (14). The number of patients whose 
condition improved or worsened was calculated and the 
significance level was determined with use of the binomial 
distribution with p = 0.5. 
The incidences of clinical and laboratory adverse effects 
in this study were compared for the two treatment groups 
with use of Fisher’s exact test. For laboratory tests, the 
proportions of patients exceeding predefined limits of change 
were also compared with this method. The predefined limits 
of change for blood urea nitrogen (> 10 mg/dl) and creatinine 
(>0.3 mgldl) are changes >2 SD from the intertest variability 
observed in a healthy person over a 2 week time period (15). 
All p values were rounded to two decimal places and 
statistical significance was declared if the rounded p value 
was 50.05. 
Results 
Patient characteristics and comparability. One hundred 
eighty-nine patients from 16 centers in the United States 
entered this double-blind study; 94 were randomized to the 
lisinopril group and 95 to the captopril group (Table 1). The 
treatment groups were similar at baseline with respect to key 
demographic and efficacy variables (Table 1). 
The most frequently reported secondary diagnoses were 
essential hypertension, diabetes mellitus, gout and angina 
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Table 1. Baseline Demographic and Efficacy Variables in 
189 Patients 
Variable 
Age (yr) 
Duration of diagnoses tyr) 
Exercise duration ts) 
Lisinopril Captopril 
Mean Mean 
In = 94) (n = 95) 
61.3 59.1 
3.6 3.7 
468.1 485.4 
n (70) 
Gender 
Male 71 (76) 
Female 23 (24) 
Race 
Black 23 (24) 
Not black 71 (76) 
Etiology of heart fatlure 
Cardiomyopathy 42 (45) 
Coronary heart disease 36 (3X) 
Hypertension IO (11) 
Valvular heart disease 5 (5) 
Other I (1) 
New York Heart Association status 
Class II 28 (31) 
Class III 55 (61) 
Class IV 7 (8) 
No significant differences between treatment groups. 
n t%‘/r) 
77 (81) 
18 (19) 
28 (291 
67 (71) 
45 (47) 
28 (29) 
13 (14) 
6 (6) 
3 (4) 
29 (31) 
5X 162) 
7 171 
pectoris. The treatment groups were comparable with re- 
spect to secondary diagnoses, except that significantly more 
patients in the lisinopril group had a secondary diagnosis of 
angina pectoris. 
The treatment groups were also generally comparable 
with respect to concomitunt medications. Ninety-three pa- 
tients treated with lisinopril (99%) and 90 patients treated 
with captopril (95%) received digoxin during the study and 
93 patients treated with lisinopril (99%) and 93 treated with 
captopril (98%) received one or more diuretics. Seven pa- 
tients (five treated with lisinopril, two with captopril) were 
treated concomitantly with a beta-adrenergic blocking agent. 
Because in all but one patient the dose of beta-blocker was 
constant throughout the study, it is unlikely that the results 
were influenced by the use of beta-blockers. 
Dose utilization. The number of patients receiving each 
dose (expressed as total daily dose) of investigational drug at 
the end of the study was as follows: lisinopril. 5 mg (21 
patients; 22%): lisinopril, 10 mg (29; 31%); lisinopril, 20 mg 
(44; 47%); captopril, 137.5 mg (20; 21%); captopril, 38 to 75 
mg (25; 26%); captopril, 76 to 150 mg (50; 53%). 
The distribution of patients over the low, middle und high 
dosages was quite similar for the two treatment groups. 
About half of the patients were titrated to the highest 
permissible dose in each treatment group. 
Blood pressure decreases after the first dose. The peak 
decrease in blood pressure after the first dose of active 
-201 ’ ’ ’ ’ ’ ’ ’ ’ ’ 
0 1 2 3 4 5 6 7 6 
Hours Post Dose 
Figure 1. Mean change in sitting systolic and diastolic blood pres- 
sure (BP) after the first dose of lisinopril or captopril. 1’ and 3 = 
significant differences between treatment groups; p 5 0.05 and p % 
0.01~ respectively. 
double-blind medication occurred earlier in the captopril 
group (approximately 2 h after the dose) than the peak 
decrease in the lisinopril group (5 or 6 h after the dose), but 
the peak decrease in the lisinopril group was as large, or 
larger, than that in the captopril group and was of a longer 
duration (Fig. 1). 
The two treatment groups were quite similur with respect 
to clinically important (symptomatic) hypotension: two pa- 
tients receiving captopril had serious hypotension but the 
drug was not discontinued, and in two patients, lisinopril 
was discontinued because of hypotension that was not 
considered to be serious. 
Eficacy Measurements 
Exercise duration. The mean increase in exercise dura- 
tion became greater with time in both treatment groups (Fig. 
2). The mean increase at week 12 was 137 s in the lisinopril 
group and 120 s in the captopril group when all patients were 
included (p = NS). When protocol violators were excluded 
Figure 2. Mean change in treadmill exercise duration after receiv- 
ing lisinopril (circles) or captopril (squares). All increases from 
baseline were significant (p < 0.01). 
800 r 
(N=86) 
4CQ- 
300 I I I I 
0 4 a 12 
Weeks 
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Serum Crealinina 21.6 Serum Crehine 51.6 
6ecQnds 6econds 
150 r 146 ‘60 I- 
Figure 3. Mean change in exercise from baseline to 12 weeks of 
treatment with lisinopril 6r captopril in patients with normal versus 
impaired renal function. 
from the analysis, lisinopril was superior to captopril (162 
versus 133 s, respectively, p < 0.05). 
Changes in exercise duration were analyzed within six 
prospectively determined patient subgroups at week 12. The 
subgroups considered were older patients (265 years), 
younger patients (564 years), black patients, nonblack pa- 
ti$s, renally impaired patients (serum creatinine 21.6 mgi 
dl [?141 ~moVliter] at baseline) and patients with normal 
renal function (serum creatinine cl.6 mg/dl [<141 pmoli 
liter] at baseline). The increase in exercise duration from 
baseline was statistically significant within each subgroup in 
both the lisinopril and captopril group. 
The improvement in exercise capacity was similar for 
patients without baseline renal impairment treated with 
either captopril or lisinopril (Fig. 3). However, captopril was 
significantly less effective than lisinopril in patients with 
serum creatinine 2 1.6 mg/dl (2 14 1 pmol/liter). 
There was no difference in efficacy of either drug in 
blacks versus nonblacks or in younger versus older patients. 
Functional assessments and quality of life (New York Heart 
Association classification, patient’s global assessment of prog- 
ress and the Yale Scale dyspnea/fatigue index). Improve- 
ments in functional classification were similar in the lisino- 
pril and captopril groups. The condition of 28 patients in the 
lisinopril group and of 29 in the captopril group improved; 
however, the condition of 3 patients in the captopril group, 
versus none in the lisinopril group, deteriorated. The distri- 
bution of patients’ global evaluation was also similar for the 
two treatment groups; 54 patients receiving lisinopril (59%) 
considered themselves to have moderate or much improve- 
ment at the end of the study compared with 50 patients 
receiving captopril (53%). 
The Yale Scale dyspneaifatigue index assessed the pa- 
tients’ ability to perform tasks of daily living (16). Both 
treatment groups showed significant improvement (p 5 0.01) 
from baseline, bui the degree of improvement was greater in 
the lisinopril group (+ 1.54) than in the captopril group 
(+1.15, p 5 0.05). 
Left ventricular ejection fraction and cardiothoracic ratio. 
Radionuclide ejection fraction improved significantly in the 
lisinopril group (p < 0.01) but not in the captopril group (Fig. 
4). A comparison of the effects of treatment on patients with 
a baseline left ventricular ejection fraction ~35% revealed an 
increase after lisinopril (p < 0.0001) but not after captopril; 
the intergroup difference was significant (p < 0.05). The 
cardiothoracic ratio improved significantly over baseline in 
both groups (p 5 0.01 for each group). 
Symptoms and signs of heart failure. All symptoms and 
signs of congestive heart failure were significantly decreased 
with both treatments with the exception of rales and jugular 
venous distension, which were not significantly decreased 
from baseline levels in the captopril group. 
Adverse Experiences 
Clinical adverse experiences (Table 2). During the double- 
blind period, clinical adverse experiences occurred in 33 of 
the patients receiving lisinopril (35.1%) and 45 of those 
receiving captopril (47.4%) (p = NS). Three patients (3.2%) 
receiving captopril died; no patient receiving lisinopril died 
during double-blind therapy. More patients receiving capto- 
pril (11 patients, 11.6%) than patients receiving lisinopril (3 
patients, 3.2%) had serious adverse experiences during the 
double-blind period (p < 0.05). The three serious adverse 
experiences occurring in the lisinopril group during the 
double-blind period were small bowel necrosis (one patient), 
AU PATENTS 
CAPlOFmL 
(-56) 
4.1 
I 
LlSlNOPRlL 
(“56) 
PATIENTS WITH BASELINE 
i 35s. EJECTION FRACTlON 
CAPTOPRIL USINOFRIL 
(n=44) (“30) 
Figure 4. Mean change in ejection fraction from base- 
line to 12 weeks of treatment with lisinopril or captopril 
in all patients versus patients with baseline ejection 
fraction 535%. 
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Table 2. Most Common Clinical Adverse Experiences During 
Double-Blind Period (incidence r3%-excluding deaths) 
Lisinopril 
(n = 94) 
Adverse Experience (%‘o) 
Dizziness 6 (6.4) 
Nausea 3 (3.2) 
Angina pectorisichest pain 5 (5.3) 
Hypotension 2 (2.1) 
Diarrhea 2 (2.1) 
Rash l(l.1) 
Upper respiratory symptoms 3 (3.2) 
Dyspnea l(1.1) 
Fatigue l(l.l) 
Vomiting 0 
Palpitation l(l.1) 
Asthenia 0 
No significant differences between treatments. 
Captopril 
tn = 95) 
W) 
5 (5.3) 
6 (6.3) 
3 (3.2) 
4 (4.3) 
4 (4.2) 
5 (5.3) 
3 (3.2) 
4 (4.2) 
3 (3.2) 
4 (4.2) 
3 (3.2) 
3 13.2) 
pulmonary infarction (one patient) and elevation of liver 
enzymes and serum creatinine due to worsening congestive 
heart failure (one patient). In the captopril group, the 11 
serious adverse experiences included sudden death (3 
patients), hypotension (2 patients), angina (2 patients). 
hypertensive crises and hyponatremia (1 patient), pulmonary 
edema (1 patient), cerebrovascular accident (1 patient) and 
dizziness, nausea and vomiting (1 patient). The most com- 
mon clinical adverse experiences (occurring in 23% of either 
group) are listed in Table 2. 
Laboratory adverse experiences. Renal function. During 
the double-blind period, elevations in blood urea nitrogen 
>I0 mg/dl (in 19 of 90 [21%]) and creatinine >0.3 mg/dl (in 13 
[ 14%] of 90) were more frequent and greater in magnitude in 
the lisinopril group as compared with elevations in blood 
urea nitrogen (in 5 [6%] of 91) and creatinine (in 9 (lo%] of 
91) in the captopril group. The difference between groups 
was statistically significant for blood urea nitrogen (p 5 0.01) 
but not for serum creatinine. The mean increase in blood 
urea nitrogen was 3.9 mgidl in the lisinopril group and 1.0 
mgidl in the captopril group. The mean increase in creatinine 
was 0.1 mg/dl in the lisinopril group; there was no increase in 
creatinine in the captopril group. 
Hyperkalemia. Clinically important hyperkalemia (>5.7 
mEq/liter or mmollliter) was observed in two patients receiv- 
ing lisinopril and three receiving captopril during the double- 
blind period. One patient in the lisinopril group was taking a 
potassium-sparing diuretic and two patients in the captopril 
group were taking a potassium supplement. Two patients 
receiving captopril were diabetic. One patient was discon- 
tinued from the long-term lisinopril extension because of 
renal impairment and a serum potassium level of 8.6 mEq/ 
liter (8.6 mmoliliter). She had been receiving concomitant 
therapy with spironolactone. 
Discussion 
LisinopriI versus captopril. The addition of either lisino- 
pril or captopril to a regimen of diuretics or digoxin, or both, 
for the treatment of congestive heart failure resulted in 
comparable improvement in exercise duration. However, 
improvement in functional capacity and quality of life was 
greater in the lisinopril group when compared with that of 
the captopril group, as shown by a difference in the Yale 
Scale-dyspnea’fatigue index. Left ventricular ejection frac- 
tion increased significantly for patients receiving lisinopril 
but not for patients receiving captopril: among patients with 
left ventricular ejection fraction <35%, the improvement in 
those receiving lisinopril was significantly greater than that 
in patients receiving captopril (p < 0.05). A previous study 
(17) also found that captopril did not increase left ventricular 
ejection fraction. 
Left ventricular function and survival. Improvement in 
left ventricular systolic function, as seen with lisinopril, may 
have prognostic implications. Not only is left ventricular 
ejection fraction an independent predictor of mortality in 
congestive heart failure (18), but treatment of congestive 
heart failure with a regimen that increases ejection fraction 
(for example, hydralazine plus isosorbide dinitrate) im- 
proves survival. whereas regimens that do not increase 
ejection fraction (for example, prazosin) are not associated 
with improved survival (19). Thus. long-acting angiotensin- 
converting enzyme inhibitors may improve survival by sig- 
nificantly improving left ventricular systolic function (5). 
Role of renal impairment. An unexpected finding of this 
study was that the therapeutic effect of lisinopril was not 
influenced by the degree of renal impairment. It has been 
reported (20) that among patients with congestive heart 
failure captopril is less effective with respect to improvement 
in hemodynamic variables in patients who have renal impair- 
ment than in patients with normal renal function, an obser- 
vation supported by this study. However, lisinopril had 
similar efficacy in patients with and without renal impair- 
ment and was significantly better than captopril in improving 
exercise capacity in patients with impaired renal function 
(Fig. 3). 
Mechanisms of therapeutic improvement with lisinopril. 
The reason for the superiority of lisinopril over captopril in 
improving left ventricular ejection fraction and in improving 
exercise tolerance in renally impaired patients is not re- 
vealed by this study. These effects could be due to a number 
of possible differences between captopril and lisinopril, 
including chemical structure, means of binding to angioten- 
sin-converting enzyme, potency, pharmacokinetics, phar- 
macodynamics (21), duration of action (6) or the degree of 
inhibition of tissue-specific angiotensin-converting enzymes 
(20). The effect of systemically administered angiotensin- 
converting enzyme inhibitors on specific tissue renin- 
angiotensin systems, for example, heart. blood vessels and 
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brain, may be important in mediating therapeutic effects and 
are variably affected by different angiotensin-converting 
enzyme inhibitors (22). In this study, the prolonged duration 
of cardiac unloading produced by lisinopril might explain the 
increased improvement in left ventricular ejection fraction 
achieved with this agent compared with that achieved with 
captopril. Also, the improvement in exercise duration in the 
renally impaired patients receiving lisinopril could be related 
to the degree of inhibition of intrarenal angiotensin- 
converting enzymes or more relaxation in efferent arteriolar 
tone, or both. The various angiotensin-converting enzyme 
inhibitors may have differing effects on the pathophysiology 
of congestive heart failure. 
Blood pressure effects. The decrease in blood pressure 
after initial doses of investigational drugs was similar for 
captopril (12.5 mg) and lisinopril (5 mg), but the maximal 
decrease occurred within 2 h after captopril dosing and did 
not occur until 5 to 6 h after lisinopril dosing. The longer 
duration of action of lisinopril and the more gradual decrease 
in blood pressure achieved with this drug may require the 
physician to monitor some patients (depending on their 
clinical status) for a longer period of time after the first dose 
of lisinopril. Symptomatic hypotension was reported in only 
two patients receiving captopril, but lisinopril therapy was 
discontinued in two patients because of mild, nonserious 
hypotension. In the present study, the starting dose for 
captopril was 12.5 mg three times a day, titrated to 50 mg 
three times a day, which may explain the lower incidence of 
hypotension in the captopril group as compared with that in 
published studies. 
Changes in renal function. Elevations in blood urea nitro- 
gen and creatinine, as well as clinically significant deteriora- 
tion in renal function, are well recognized effects of an- 
giotensin-converting enzyme inhibitors in certain 
predisposed patients (6). In this study, lisinopril showed a 
greater tendency than did captopril to produce these changes 
in blood urea nitrogen, although the two drugs did not differ 
significantly in their propensity to increase serum creatinine. 
The changes in blood urea nitrogen were small and not 
considered clinically important. These changes were easily 
reversible by decreasing the dose of diuretic or either 
lisinopril or captopril, or both. 
Conclusions. Treatment with either the long-acting an- 
giotensin-converting enzyme inhibitor lisinopril once a day 
or the short-acting angiotensin-converting enzyme inhibitor 
captopril three times a day for 12 weeks in a double-blind, 
randomized study was well tolerated and efficacious in these 
patients with congestive heart failure (New York Heart 
Association classes II to IV). Lisinopril and captopril were 
similar in improving exercise duration; however, lisinopril 
was superior in improving ejection fraction, functional ca- 
pacity and quality of life in this group, and produced fewer 
serious adverse experiences. 
Appendix 
Participating Individuals and Institutions in the Multicenter 
Lisinopril-Captopril Congestive Heart Failure Study Group are: 
Anthony Chiaramida, MD, Salvatore Chiaramida, MD, Vicki 
Uhrin, RN, Perth Amhoy General Hospital, Perth Amhoy, NJ. 
Anthony N. DeMaria, MD, Michael Harrison, MD, Cara Muffly, 
RN, Lee Ann Crawley, RN, University of Kentucky, College of 
Medicine, Lexington, KY. 
Thomas D. Giles, MD, M. George Thomas, MD, Antonio C. 
Quiroz, MD, Gary E. Sander, MD, Louise Roffidal, RN, Tulane 
University Medical Center, New Orleans, LA. 
Barry Hackshaw, MD, Henry S. Miller, Jr., MD, Joyce Charles, 
RN, Bowman Gray Medical School, Winston-Salem, NC. 
William Hart, MD, Daniel S. Clark, MD, Rosemary Lucey, RN, 
Ventura Cardiology Consultants, Ventura, CA. 
Mark Haugland, MD, Philip Ranhiem, MD, Bonnie Kueng, RN, 
Park Nicollet Medical Center, Minneapolis, MN. 
Robin Johnston, MD, Kip Richards, RN, Mason Clinic, Seattle, 
WA. 
Richard Katz, MD, Harold Copans, MD, Carol Zachman, RN, 
Alvarado Medical Plaza, San Diego, CA. 
Philip Kirlin, MD, Park Willis III, MD, Carolyn Koestner, RN, 
Cindy Dansby RN, Michigan State University, East Lansing, MI. 
Marvin McCall, MD, Mary P. Baucom, MD, Brenda Smith- 
Borucki, RN, Charlotte Memorial Hospital, Charlotte, NC. 
Syed Mohiuddin, MD, Lois Stengel, RN, Creighton University, 
Omaha, NE. 
Eric Powers, MD, Steven Corwin, MD, Edith Escala, RN, 
Columbia Presbyterian Hospital, New York, NY. 
Stuart Rich, MD, Jeffrey G. Shanes, MD, Karen Kalamatus, 
RN, University of Illinois Hospital, Chicago, IL. 
Jay M. Sullivan, MD, Marshall B. Elam, MD, Beatte Griffin, 
RN, University of Tennessee, Memphis, TN. 
J. L. Rouleau, MD, Hospital due Sacu Coeur, 5400 Boulevard 
Gouin 0, Montreal, Quebec, Canada. 
Paul Wolfson, DO, David B. Braunstein, DO, Sarah Dunlap, 
RN, Chicago College of Osteopathy, Chicago, IL. 
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